How a Wearable Radio Frequency Device May Help Reverse Alzheimer’s Disease

Alzheimer’s disease treatment has long been dominated by drug therapies targeting amyloid plaques, many of which carry serious side effects and only modestly slow decline. In a recent episode of the Alzheimer’s Breakthrough podcast, Dr. Josh Helman spoke with Chuck Papageorgiou, CEO of NeuroEM Therapeutics, about a revolutionary non-invasive approach. Their wearable head device uses Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) to deliver targeted energy to the brain. This breakthrough technology, born from an unexpected discovery, is showing incredible promise in stabilizing and even reversing cognitive decline.

An Accidental Discovery Born From Cell Phone Radiation Research

NeuroEM’s technology traces back to 2013 and 2014, during widespread fears that cell phone radiation caused brain cancer. Dr. Gary Arendash, a neuroscientist at the University of South Florida, decided to test continuous cell phone signals on mice with Alzheimer’s. Not only did the mice avoid developing brain cancer, but they actually showed reversed cognitive decline in water maze testing. The experiment was successfully repeated in multiple labs globally. This led to a clinical trial where seven out of eight human patients experienced a halt or reversal in cognitive decline.

How Radio Frequency Energy Targets Amyloid, Tau & Brain Inflammation

Unlike a standard cell phone that emits a continuous background signal, the NeuroEM device delivers short, carefully controlled radio frequency pulses through antennas positioned around the head. It operates in the ISM band (around 815 MHz), which is the same frequency range used by cell phones and Bluetooth. According to Papageorgiou, this photonic energy does three critical things: it disrupts the abnormal structures of amyloid beta and tau proteins so the brain’s glymphatic system can clear them out at night, it impacts the mitochondria to increase ATP (brain fuel) production, and it rebalances cytokine levels to reduce inflammation.

A Slow, Gentle Process Designed to Avoid Side Effects

Many anti-amyloid drug therapies, such as lecanemab and aducanumab, carry significant risks of brain swelling and bleeding in up to a third of patients because they aggressively clear amyloid all at once. Papageorgiou explains that the NeuroEM device takes a slow, gentle approach to avoid overwhelming the lymphatic system. It is programmed to run for exactly one hour and physically cannot be turned back on for another seven hours. Because of this gradual approach, patients typically do not notice changes for four to eight weeks, but it completely avoids the severe hemorrhage risks associated with fast-acting drugs.

Inside the Device: Comfortable, Data Tracking & Built for Daily Use

The wearable cap was engineered to be unobtrusive and easy for daily home use. It requires no messy gels; instead, it uses a simple cloth barrier over the antennas to ensure there is no direct skin contact. Powered by small rechargeable batteries, it is completely wireless. It also functions as a smart device that records usage compliance and the amount of power transmitted and dissipated, data that NeuroEM uses to track patient progress. For safety, the device will immediately shut down and disconnect its batteries if it gets wet.

Real Patient Results: Reversing Years of Cognitive Decline

Papageorgiou described the remarkable case of a patient named Marty, who was diagnosed with moderate Alzheimer’s at age 84. After starting the treatment, she continued to decline for the first two months, stabilized by month three, and showed measurable improvement by month five. Eventually, she regained two years’ worth of lost cognitive scoring, and at age 91, she scored in the normal range for her age. In another case, a patient with tauopathy experienced such significant neurological improvement after six months of treatment that he failed to qualify to have his driver’s license taken away by the state of California.

Behavior and Mood Often Improve Before Cognitive Scores Do

A recurring pattern is that caregivers notice behavioral changes long before formal cognitive test scores shift. Around six to eight weeks into treatment, families frequently report a returning “spark” in the patient’s eye, improved patience, and a better attitude. Even in patients with rare forms of dementia where cognitive scores have not improved, families insist on continuing the treatment because the patient’s attitude and mood remain consistently positive.

Safety Data, Electromagnetic Sensitivity & Who Should Use It

The FDA has granted NeuroEM’s clinical device a breakthrough designation as well as a non-significant risk (NSR) designation. Extensive safety testing confirms that the device does not raise the temperature of the brain by more than 1°C. Furthermore, a 20-year longitudinal study by the U.S. Army showed no negative long-term effects from using radio frequencies in this band. The device has shown no interference with pacemakers, and the company is even currently studying patients who self-report high sensitivities to electromagnetic fields (EMF) via MRI.

How It Compares to Ultrasound, TMS & Other Emerging Brain Technologies

Papageorgiou views NeuroEM’s technology as complementary to other emerging treatments. For instance, focused ultrasound paired with MRI is a brilliant technology that temporarily loosens the blood-brain barrier for better drug delivery, but it requires an expensive clinical setting. Transcranial Magnetic Stimulation (TMS) uses indirect magnetic fields, whereas NeuroEM delivers energy directly into the brain. Papageorgiou warns against unregulated treatments, like buying “healing crystals” on Amazon, emphasizing the importance of validated, data-backed technologies.

What’s Next: Clinical Trials, Alzheimer’s Treatment Centers & Wider Access

NeuroEM is expanding its clinical trials, including a new 15-person study with CareOne and an upcoming Institutional Review Board (IRB) protocol with Alzheimer’s Treatment Centers of America (ATCA). While full FDA clearance to make medical claims for Alzheimer’s is still three to four years away, NeuroEM has already received clearance for a lower-power version of the device. This consumer version, aimed at general brain health and wellness, is expected to launch under a new brand within the next year.

Key Takeaways

• A wearable radio frequency device utilizing the ISM band (815 MHz) has demonstrated the ability to stabilize and improve cognitive decline in Alzheimer’s patients.
• The therapy uses short pulses of energy to safely break down amyloid and tau, boost ATP energy production, and reduce inflammation.
• By limiting usage to one hour with a seven-hour rest period, the device gently clears proteins, avoiding the brain swelling and bleeding risks associated with antibody drugs.
• Caregivers often notice a return of the patient’s “spark” and improved mood around six to eight weeks, well before cognitive scores improve.
• The device is designed for easy, wireless, daily home use with no gels and records compliance data for medical monitoring.
• A consumer wellness version for general brain health is expected next year, though clinical Alzheimer’s approval is still years away.

Conclusion

This conversation highlights a very different path forward in Alzheimer’s disease treatment, one built on targeted radio frequency energy rather than pharmaceuticals. Early data from NeuroEM’s wearable device points to meaningful improvements in both behavior and cognition for some patients, though larger clinical trials are still ongoing to confirm these results at scale. For patients and families exploring non-drug approaches to cognitive decline, any new device or therapy should be discussed with a qualified physician, since individual response can vary based on disease stage, prior treatment history, and overall brain health.